Blue Cross Blue Shield mandates severe asthma patients self-administer drugs at home, unless their provider gets prior approval from the company.

Nearly 5 million children in the U.S. have asthma, a disease that narrows the airways. While there's no cure, it can be ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients ...

Millions of U.S. children have asthma and benefit from taking anti-inflammatory medications at least once a day as prescribed by their health care provider. This school-based asthma therapy program ...

But for at least one of the drugs, Xolair, the reaction can also happen up to a year into treatment. Many families are not comfortable administering biologics to their kids with severe asthma ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Preliminary Data From SNY's Asthma Study on Amlitelimab Preliminary data from the TIDE-Asthma study showed that treatment with the ... SNY markets blockbuster asthma drug Dupixent (dupilumab ...

The change will make asthma ... treatment has begun, the label warns. The manufacturer states that anaphylaxis has been found to occur in just 0.1% of patients. Over-the-counter pain medications ...